Eclosion Ventures

Eclosion Ventures

Eclosion Ventures manages the Eclosion life science investment fund, operating from Geneva's Campus Biotech. The fund concentrates on translating early-stage academic science into standalone biotechnology companies. Its portfolio targets high unmet medical needs, building startups around novel therapeutic and platform technologies from discovery through to clinical validation. The firm deploys capital exclusively through direct equity investments in seed-stage biotech startups, holding these positions until clinical proof of concept. Portfolio companies have advanced first-in-class drug candidates in multiple sclerosis, fibrosis and oncology. Eclosion’s approach combines capital with significant operational support, embedding a builder mentality into each venture rather than acting as a passive minority investor. Eclosion operates as a single-entity, sector-specialist manager from its headquarters in Geneva, Switzerland. The firm has not disclosed fund sizes, team headcount, or portfolio company names in the publicly available record. It provides a web contact form but no named investment team members or external publications. Eclosion’s architecture as a dedicated life-science builder without a disclosed parent or multi-asset sibling sets it apart from generalist venture platforms. Its structure demands that all fund-level resources — scientific vetting, operational expertise, and capital — converge on a narrow set of early-stage therapeutic companies, creating an unusually concentrated risk and support profile.